Best CDMOs in Asia — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
35
CDMOs in region
35
Fully scored
9
With FDA records
23
FDA inspections
68
EMA/MHRA GMP certs
CDMO Signal tracks 35 biopharma CDMOs with confirmed Asia manufacturing facilities, of which 35 are fully scored across the four-pillar composite Signal Score. Across all modalities, Pharmaron Biologics, Ajinomoto Bio-Pharma Services, and Minaris Advanced Therapies lead the Asia ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within Asia — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.
Asian CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed Asia-Pacific facilities (Japan, South Korea, China, India, Singapore, and adjacent APAC geographies). This ranking is the subset of our global directory with Asian manufacturing presence — a CDMO with Asia + US + EU sites appears in each corresponding region ranking. Filtering is derived from each CDMO's declared facility locations.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 2 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 3 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.3 | 99.6 | 1 insp · 6 GMP | Limited | 0 programs |
| 4 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.3 | 95.0 | 5 insp · 13 GMP | — | 0 programs |
| 5 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
82.9 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 6 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
81.6 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 7 |
GS
GenScript ProBio
Piscataway, NJ · Nanjing, CN
|
79.5 | 100.0 | — | Constrained | 0 programs |
| 8 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
78.6 | 100.0 | 2 insp · 23 GMP | Available | 2 programs |
| 9 |
SG
Syngene International
Bengaluru, India
|
78.5 | 96.3 | 2 insp · 0 GMP | — | 0 programs |
| 10 |
PBI
ProBio
Taipei, Taiwan
|
78.1 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 11 |
BC
Biocon Biologics
Bengaluru, India
|
77.6 | 97.1 | 4 insp · 2 GMP | — | 0 programs |
| 12 |
SP
ST Pharm
Seoul, South Korea
|
73.2 | 89.4 | 2 insp · 4 GMP | — | 0 programs |
| 13 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
71.5 | 85.8 | 3 insp · 0 GMP | Available | 0 programs |
| 14 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.3 | — | — | — | 49 programs |
| 15 |
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
|
65.7 | 73.3 | 0 insp · 1 GMP | — | 0 programs |
| 16 |
GenScript
Piscataway, NJ (US HQ); Nanjing, China (primary operations)
|
64.0 | — | — | — | 0 programs |
| 17 |
HG
Hitachi Global Life Solutions (CGT)
Yokohama, Japan
|
63.0 | — | — | — | 0 programs |
| 18 |
SM
Sumitomo Chemical Advanced Medical
Tokyo, JP
|
63.0 | — | — | — | 0 programs |
| 19 |
EA
Esco Aster
Singapore, SG
|
63.0 | — | — | — | 0 programs |
| 20 |
AU
Aurigene Pharmaceutical Services
Hyderabad, India
|
63.0 | — | — | — | 0 programs |
| 21 |
SB
Samsung Biologics
Incheon, South Korea, Rockville, Maryland, USA
|
61.5 | — | — | Available | 0 programs |
| 22 |
Minaris (WuXi Advanced Therapies)
Philadelphia, PA / Yokohama, Japan
|
60.5 | — | — | — | 0 programs |
| 23 |
HX
Helixmith
Seoul, KR
|
59.0 | — | — | — | 0 programs |
| 24 |
CTP
Cell Therapies Pty Ltd
Melbourne, Australia
|
59.0 | — | — | — | 0 programs |
| 25 |
RR
RiboBio
Guangzhou, China
|
59.0 | — | — | — | 0 programs |
| 26 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| 27 |
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
|
57.9 | — | — | — | 8 programs |
| 28 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
56.5 | — | — | — | 0 programs |
| 29 |
GC
Green Cross Cell
Yongin, KR
|
56.5 | — | — | — | 0 programs |
| 30 |
CH
CHA Medical & Bio Group
Seongnam, KR
|
56.5 | — | — | — | 0 programs |
| 31 |
HB
Hongene Biotech
Singapore (primary operations: Union City, CA / Shanghai, China)
|
56.5 | — | — | — | 0 programs |
| 32 |
EP
Exopharm
Melbourne, AU
|
56.5 | — | — | — | 0 programs |
| 33 |
CLB
Clara Biotech
Indianapolis, IN
|
56.5 | — | — | — | 0 programs |
| 34 |
IC
INCOG BioPharma Services
Fishers, IN
|
56.5 | — | — | — | 0 programs |
| 35 |
IP
Intas Pharmaceuticals
Ahmedabad, India
|
51.4 | 45.5 | 0 insp · 5 GMP | — | 0 programs |
Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)
Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.
Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?
Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.
Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)
Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.
Browse by modality within Asia
Modality-specific rankings for Asia-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed Asia facilities.
AAV / Gene Therapy (9)
CAR-T (9)
Lentiviral Vector (6)
Cell Therapy (16)
mRNA / LNP (4)
Plasmid DNA (3)
Biologics / mAb (9)
Oligonucleotide / ASO (6)
Gene Editing (1)
Exosome / Extracellular Vesicle (3)
Recombinant Proteins (3)
ADC (Antibody-Drug Conjugate) (4)
Gene Therapy (10)
Cell & Gene Therapy (24)
Viral Vector (10)